Q-omics provides the consensus-scored GAPDHP28 profile across patient tissues and cancer cell-line models. GAPDHP28 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, GAPDHP28 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, GAPDHP28 RNA expression shows 5,910 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight MESO, KIRC, and ESCA as cancer lineages where GAPDHP28 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAPDHP28 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAPDHP28 survival associations across molecular data types. GAPDHP28 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAPDHP28 RNA expression–survival associations across cancer types. High GAPDHP28 expression shows unfavorable associations in HNSC and SARC, but favorable associations in MESO, READ, LUSC and OV. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .016). Together, the overview and detailed table identify MESO as the clearest survival context for GAPDHP28 RNA expression.
This table summarizes GAPDHP28 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GAPDHP28. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAPDHP28 shows higher tumor expression in KIRC, UCEC, LUSC, BRCA, COAD and HNSC. The KIRC box plot shows higher GAPDHP28 RNA expression in tumor versus normal tissue (log2 FC = +0.065, t-test p < 0.001).
This table shows molecular features associated with GAPDHP28 in patient tissues and cancer cell lines. In patient samples, GAPDHP28 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
